Epidemiology and clinical characteristics of bladder tumors recorded in a reference hospital in the Yucatan PeninsulaR TUMORS IN A REFERRAL HOSPITAL IN THE YUCATAN, PENINSULA.
DOI:
https://doi.org/10.48193/3adrvz79Keywords:
vertical cancer, prevalence, vertical tumorsAbstract
Introduction: in Mexico, bladder tumors rank fourth in urological tumor presentation, accounting for 14.4 % of cases, following prostate, testicular, and kidney cancer. The male-to-female ratio is 3.8:1. Bladder cancer is one of the main causes of consultation in patients with macroscopic hematuria and clot formation. Therefore, it should always be considered as an exclusion diagnosis in these patients due to its potential progression and impact on morbidity and mortality if detected in advanced stages.
Objectives: to determine the prevalence and clinical characteristics of registered cases of bladder cancer in the urology department.
Materials and methods: this is a descriptive, observational, cross-sectional study that will evaluate the medical records of patients with registered cases of bladder cancer in the Urology Department of the Hospital Regional de Alta Especialidad de la Península de Yucatán in Mexico, from from January 2017 to July 2021.
Results: of total 453 genitourinary tumors, 15.62 %, 29 patients with bladder tumor and a 4-year medical follow-up were included, bladder tumor is predominantly found in men with a male-to-female ratio of 3.83 men per woman. The mean age at diagnosis is 65 years. Among modifiable risk factors, smoking is the main factor affecting 44.8 % of the cases. According to the histological classification, the predominant subtype was urothelial carcinoma. The average time from symptom onset to medical attention by the patients was 11.9 months. T4 stage was detected in 27.59 % of the cases, with a mortality rate of 6.9 %.
Conclusion: bladder cancer is one of the three most common urological cancers, affecting the quality of life and with a high morbidity and mortality when detected at advanced stages, requiring aggressive surgical procedures with a high risk of complications.
References
de la Rosa-Cisneros AR, Viveros-Contreras C, Torres-Aguilar J, Hernández-León O, Arellano-Cuadros R, Martínez-Carrillo G. Experiencia en el tratamiento de cáncer vesical. Revista Mexicana de Urología. 2015;75(2): 58–63. https://doi.org/10.1016/j.uromx.2015.01.001
Sedano-Basilio JE, Mayorga-Gómez E, Garza-Sainz G, Cornejo-Dávila V, Uberetagoyena-Tello de Meneses I, Palmeros-Rodríguez AM, et al. Epidemiología de los tumores genitourinarios en una década. Revista Mexicana de Urología. 2016;76(3): 131–140. https://doi.org/10.1016/j.uromx.2016.01.004.
Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World Journal of Urology. 2020;38(8): 1895–1904. https://doi.org/10.1007/s00345-019-02984-4.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6): 394–424. https://doi.org/10.3322/caac.21492.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology. 2017;71(1): 96–108. https://doi.org/10.1016/j.eururo.2016.06.010.
Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nature Reviews. Disease Primers. 2017;3: 17022. https://doi.org/10.1038/nrdp.2017.22.
Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, et al. Epidemiology, Screening, and Prevention of Bladder Cancer. European Urology Oncology. 2022;5(6): 628–639. https://doi.org/10.1016/j.euo.2022.10.003.
Lenfant L, Cancel-Tassin G, Gazut S, Compérat E, Rouprêt M, Cussenot O. Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. BJU international. 2021;127(3): 375–383. https://doi.org/10.1111/bju.15254.
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Medical Sciences (Basel, Switzerland). 2020;8(1): 15. https://doi.org/10.3390/medsci8010015.
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19): 1980–1991. https://doi.org/10.1001/jama.2020.17598.
Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology. 2021;79(1): 82–104. https://doi.org/10.1016/j.eururo.2020.03.055.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology. 2018;74(6): 784–795. https://doi.org/10.1016/j.eururo.2018.09.001.
Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA, Kim SP, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22): 5235–5242. https://doi.org/10.1002/cncr.25310
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). European Urology. 2022;81(1): 75–94. https://doi.org/10.1016/j.eururo.2021.08.010.
Rozanec JJ, Secin FP. Epidemiología, etiología, prevención del cáncer vesical. Archivos Españoles de Urología 2020; 73 (10) 872–878
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista Mexicana de Urología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
